Phase I study of single agent NIZ985, a recombinant heterodimeric IL-15 agonist, in adult patients with metastatic or unresectable solid tumors

BACKGROUND: NIZ985 is a recombinant heterodimer of physiologically active interleukin (IL-)15 and IL-15 receptor alpha. In preclinical models, NIZ985 promotes cytotoxic lymphocyte proliferation, killing function, and organ/tumor infiltration, with resultant anticancer effects. In this first-in-human...

Descripción completa

Detalles Bibliográficos
Autores principales: Conlon, Kevin, Watson, Dionysios C, Waldmann, Thomas A, Valentin, Antonio, Bergamaschi, Cristina, Felber, Barbara K, Peer, Cody J, Figg, William D, Potter, E Lake, Roederer, Mario, McNeel, Douglas G, Thompson, John A, Gupta, Sumati, Leidner, Rom, Wang-Gillam, Andrea, Parikh, Nehal S, Long, Debby, Kurtulus, Sema, Ho Lee, Lang, Chowdhury, Niladri Roy, Bender, Florent, Pavlakis, George N
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606766/
https://www.ncbi.nlm.nih.gov/pubmed/34799399
http://dx.doi.org/10.1136/jitc-2021-003388

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8606766/
https://www.ncbi.nlm.nih.gov/pubmed/34799399
http://dx.doi.org/10.1136/jitc-2021-003388

Ejemplares similares